HOXA9 and colorectal carcinoma: While many biomarkers have been shown to be viable for gastric and urinary cancers such as bladder and CRC, one study also reported a successful DNA methylation analysis (1.7) of a panel (CDO1, TAC1, HOXA7, HOXA9, SOX17, and ZFP42 promoters) to diagnose lung cancer [20].